Skip to main page content
U.S. flag

An official website of the United States government

Dot gov

The .gov means it’s official.
Federal government websites often end in .gov or .mil. Before sharing sensitive information, make sure you’re on a federal government site.

Https

The site is secure.
The https:// ensures that you are connecting to the official website and that any information you provide is encrypted and transmitted securely.

Access keys NCBI Homepage MyNCBI Homepage Main Content Main Navigation

Search Page

Filters

My Custom Filters

Publication date

Text availability

Article attribute

Article type

Additional filters

Article Language

Species

Sex

Age

Other

Search Results

145,270 results

Filters applied: . Clear all
Results are displayed in a computed author sort order. The Publication Date timeline is not available.
Page 1
A phase II study single agent of aflibercept (VEGF Trap) in patients with recurrent or metastatic gynecologic carcinosarcomas and uterine leiomyosarcoma. A trial of the Princess Margaret Hospital, Chicago and California Cancer Phase II Consortia.
Mackay HJ, Buckanovich RJ, Hirte H, Correa R, Hoskins P, Biagi J, Martin LP, Fleming GF, Morgan R, Wang L, Polintan R, Oza AM. Mackay HJ, et al. Among authors: wang l. Gynecol Oncol. 2012 Apr;125(1):136-40. doi: 10.1016/j.ygyno.2011.11.042. Epub 2011 Dec 2. Gynecol Oncol. 2012. PMID: 22138373 Free PMC article. Clinical Trial.
A phase 2 study of cediranib in recurrent or persistent ovarian, peritoneal or fallopian tube cancer: a trial of the Princess Margaret, Chicago and California Phase II Consortia.
Hirte H, Lheureux S, Fleming GF, Sugimoto A, Morgan R, Biagi J, Wang L, McGill S, Ivy SP, Oza AM. Hirte H, et al. Among authors: wang l. Gynecol Oncol. 2015 Jul;138(1):55-61. doi: 10.1016/j.ygyno.2015.04.009. Epub 2015 Apr 17. Gynecol Oncol. 2015. PMID: 25895616 Clinical Trial.
A phase I study of the combination of ro4929097 and cediranib in patients with advanced solid tumours (PJC-004/NCI 8503).
Sahebjam S, Bedard PL, Castonguay V, Chen Z, Reedijk M, Liu G, Cohen B, Zhang WJ, Clarke B, Zhang T, Kamel-Reid S, Chen H, Ivy SP, Razak AR, Oza AM, Chen EX, Hirte HW, McGarrity A, Wang L, Siu LL, Hotte SJ. Sahebjam S, et al. Among authors: wang l. Br J Cancer. 2013 Aug 20;109(4):943-9. doi: 10.1038/bjc.2013.380. Epub 2013 Jul 18. Br J Cancer. 2013. PMID: 23868004 Free PMC article. Clinical Trial.
A phase I combination dose-escalation study of eribulin mesylate and gemcitabine in patients with advanced solid tumours: a study of the Princess Margaret Consortium.
Lheureux S, Oza AM, Laurie SA, Halford R, Jonker D, Chen E, Keller D, Bourade V, Wang L, Doyle L, Siu LL, Goel R. Lheureux S, et al. Among authors: wang l. Br J Cancer. 2015 Dec 1;113(11):1534-40. doi: 10.1038/bjc.2015.343. Epub 2015 Nov 10. Br J Cancer. 2015. PMID: 26554651 Free PMC article. Clinical Trial.
Phase II trial of vorinostat in advanced melanoma.
Haas NB, Quirt I, Hotte S, McWhirter E, Polintan R, Litwin S, Adams PD, McBryan T, Wang L, Martin LP, vonMehren M, Alpaugh RK, Zweibel J, Oza A. Haas NB, et al. Among authors: wang l. Invest New Drugs. 2014 Jun;32(3):526-34. doi: 10.1007/s10637-014-0066-9. Epub 2014 Jan 25. Invest New Drugs. 2014. PMID: 24464266 Clinical Trial.
145,270 results
You have reached the last available page of results. Please see the User Guide for more information.